Introduction:
According to the results of conflicting studies regarding the role of chromium in diabetes, the purpose of this study was to investigate the effect of chromium drug administration on the mean serum levels of HbA1C, FBS and 2hpp in diabetic patients.
Methods:
In this clinical trial study, 50 diabetic patients referred to the diabetes clinic and specialized clinic of Valiasr Hospital in Birjand in 1402 were included in the study. Patients were randomly divided into two groups: 1. receiving routine medication and chromium medication (A) and 2. control (B) receiving routine medication. Selection and placement of patients in two groups was simple random and block method. At the beginning and end of the study, 5 cc of blood samples were taken from the patients and parameters of FBS, 2hpp, HbA1C and lipid profile were evaluated.
Findings:
At the end of the study, the mean serum level of FBS (P=0.002) and 2hpp (P=0.043) in the intervention group was significantly lower than the control group. The mean serum levels of triglycerides and HDL at the beginning and end of the study, LDL and cholesterol at the beginning of the study were not significantly different between the two studied groups (P>0.05). At the end of the study, the mean serum level of cholesterol (P<0.001) and LDL (P=0.007) in the intervention group was significantly reduced compared to the control group.
Discussion:
Chromium supplementation led to a significant decrease in the serum levels of FBS, 2hpp, cholesterol and LDL in diabetic patients.